Abstract
Introduction
Heart failure (HF) is a common cause of morbidity and mortality, and the incidence is increasing [1] . [3] . In normal physiology, MMPs are involved in embryonic development, wound repair and bone remodelling [4] . In a number of pathologic situations, including during all stages of HF progression, the MMP-TIMP axis plays a crucial role in ECM homeostasis [5] . MMPs are the driving force during myocardial ECM remodelling and selectively increased to mediate collagen degradation leading to LV dilation in animal models of HF and human HF [6, 7] . However, TIMPs are relatively deficient in the failing hearts [8] . Although past studies demonstrated that MMP levels are high and TIMP levels are low in human HF patients [7] 
Defects within the myocardial extracellular matrix (ECM) have been identified to directly contribute to left ventricular (LV) remodelling in the HF process [2]. ECM integrity is maintained by a balance between the activity of matrix metalloproteinases (MMPs), a family which comprises more than 25 individual members divided into specific classes based on in vitro substrate specificity for various ECM components and tissue inhibitors of metalloproteinases (TIMPs), a family currently composed of four members binding and inactivating the various MMPs

, a consistent and clear pattern of typespecific MMPs and/or TIMPs has yet to be further defined in endstage failing human hearts. Accordingly, the main goal of the present study was to clarify the type-specific dysregulation of MMPs and/or TIMPs in end-stage failing human hearts, and to further test whether cardiac and/or plasma MMP-10, one of the MMPs we identified to be up-regulated in end-stage failing human hearts, would be correlated with adverse LV remodelling.
Materials and methods
Subjects and sample collection
Protein antibody arrays
Total proteins were extracted using standard method [10] . Antibody arraybased technology was used to detect multiple proteins present in 8 
Western blot analysis
The relative abundances of MMP-10, MMP-7 and TIMP-4 were examined in individual LV myocardial protein extracts using standard immunoblotting procedures as described previously [10] . 
Cell culture and treatment
Primary neonatal rat ventricular myocytes were isolated and cultured as described previously [11] . (Fig. 3) . The diffuse staining pattern of these proteins in myocardium might reflect the fact that they are secreted. Fig. 4A and B 
We further examined the expression of cardiac MMP10, MMP-7 and TIMP-4 in failing and non-failing hearts by immunohistochemistry. Consistent with the results from protein antibody arrays and Western blot analysis, strongly immunoreactive MMP-10 and -7, and weekly immunoreactive TIMP-4 were observed in failing human hearts due to DCM, ICM and ARVC in contrast to control specimens from non-failing hearts
Cardiac and plasma MMP-10 measurement by ELISA
Cardiac and plasma MMP-10 levels were increased in HF patients with DCM (n ϭ 19), ICM (n ϭ 8) and ARVC (n ϭ 7) when compared with non-failing patients (
Correlation between MMP-10 and LV dilation
To determine which parameters in Table 1 correlated Table 1 .
with MMP-10, linear regression analyses were performed using MMP-10 as the independent variable. A positive linear correlation was observed with respect to both cardiac and plasma MMP-10 levels and LV end-diastolic dimension (LVEDD), which indicates LV remodelling and dilation, in the HF patients derived from the three forms of cardiomyopathies (Fig. 5A and B). No significant correlation was observed between MMP-10 and each of the other parameters listed in
Regulation of IGF-2 on MMP-10 production
ELISA revealed that IGF-2 induced a significant increase of cellular MMP-10 after incubation with IGF-2 (10 Ϫ6 M) for 24 hrs in primary neonatal rat cardiomyocytes (Fig. 6A). Western blot (Fig. 6B) and immunocytochemical analysis (Fig. 6C) further demonstrated that IGF-2 promoted the immunoreactive MMP-10 production after incubation with IGF-2 (10 Ϫ6 M) for 24 hrs in primary neonatal rat cardiomyocytes.
Discussion
Although the causes of HF are diverse, a common outcome in the progression of this disease process is ECM remodelling, resulting in cardiac dilation and loss of contractility. MMPs are the driving force during ECM remodelling and are selectively increased to mediate ECM degradation leading to LV dilation in animal models
of HF and human HF [5] [6] [7] . For example, using specific antisera directed against MMPs, increased levels of MMP-2, -3 and -9 in
Fig. 1 The signal intensity of cardiac MMP-10 and -7 increased and that of cardiac TIMP-4 decreased in DCM HF patients compared with those in nonfailing patients (**P Ͻ 0.01). LV myocardial samples used in this study for hybridization with protein antibody array chip were from eight DCM HF patients (DCM-HF) and eight age-and sex-matched non-failing subjects (NF).
LV myocardium from end-stage HF patients were observed [6] . [12, 13] , our particular interest is mainly focused on the relation between MMP-10 and myocardial ECM remodelling. MMP-10 degrades multiple components of the ECM, such as proteoglycan, laminin, fibronectin and collagen III and IV [14] . Past studies demonstrated that the upregulation of MMP-10 led to the abnormalities in vascular integrity [15] . MMP-10 acted as a potential biomarker and a relevant molecule in atherosclerotic vascular remodelling [16] . MMP-10 has also been shown to be associated with aortic aneurysm, characterized by destructive remodelling of the vascular ECM and rupture of the vessel wall, and are likely to contribute to disease pathogenesis [17] . Although [6, 19] , and experimental studies have demonstrated that the production of MMPs is increased in cardiac as well as other cells after stimulation by the cytokines [20, 21] 
Fig. 3 Representative immunohistochemical analysis of cardiac MMP-10, MMP-7 and TIMP-4 expression in failing and non-failing hearts. Strong immunostaining for cardiac MMP-10 and -7, and weak immunostaining for cardiac TIMP-4 were observed in failing human hearts due to DCM (DCM-HF), ICM (ICM-HF) and ARVC (ARVC-HF) in contrast to non-failing hearts (NF)
. Scale bar ϭ 50 m.
arrays, which can detect 17 species of main MMPs and all 4 species of TIMPs. We demonstrated a significant up-regulation of MMP-10 and -7 along with a down-regulation of TIMP-4 in DCM end-stage failing hearts compared with non-failing hearts, which were further validated by Western blot and immunochemistry not only in the failing hearts due to DCM, but also in the failing hearts due to ICM and ARVC. In view of that past studies have reported that both increased MMP-7 and decreased TIMP-4 are in relation to HF and myocardial ECM remodelling
